[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596416":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":10,"centralContacts":10,"locations":30,"responsibleParty":43,"collaborators":10,"id":46,"slug":10,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":10,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",[8,14,18,21],{"label":9,"type":10,"description":11,"interventionNames":12},"low-risk +1q NDMM patients",null,"This system classifies +1q NDMM patients into low, intermediate, and high-risk groups based on coexisting International Staging System (ISS) stage III, hypercalcemia, high lactate dehydrogenase (LDH), and t(14;16).Patients with ISS stage III, elevated LDH, hypercalcemia, and t(14;16) were assigned scores of 1 point, 1 point, 2 points, and 3 points, respectively. According to the tertiles of their scores,the patients with +1q were classified into low- (0 point) .",[13],"Other: risk-scoring model",{"label":15,"type":10,"description":16,"interventionNames":17},"intermediate\u002Fhigh-risk +1q NDMM patients","This system classifies +1q NDMM patients into low, intermediate, and high-risk groups based on coexisting ISS stage III, hypercalcemia, high LDH, and t(14;16).Patients with ISS stage III, elevated LDH, hypercalcemia, and t(14;16) were assigned scores of 1 point, 1 point, 2 points, and 3 points, respectively. According to the tertiles of their scores,the patients with +1q was classified into intermediate- (1-3 points) and high-risk (4-7 points) groups.",[13],{"label":19,"type":10,"description":20,"interventionNames":10},"1q negativity low-risk group","Patients with 1q negativity were included as the control group, and patients were stratified into the high-risk group and low-risk group according to the 2025 IMWG Risk Stratification.",{"label":22,"type":10,"description":20,"interventionNames":10},"1q negativity high-risk group",[24],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"risk-scoring model","This system classifies +1q NDMM patients into low, intermediate, and high-risk groups based on coexisting ISS stage III, hypercalcemia, high LDH, and t(14;16).Patients with ISS stage III, elevated LDH, hypercalcemia, and t(14;16) were assigned scores of 1 point, 1 point, 2 points, and 3 points, respectively. According to the tertiles of their scores,the patients with +1q were classified into low- (0 point),intermediate- (1-3 points), and high-risk (4-7 points) groups.",[15,9],[29],"Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma",[31],{"facility":5,"status":10,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Changchun","Jilin","130021","China","CN",{"type":38,"coordinates":39},"Point",[40,41],125.32278,43.88,{"lat":41,"lon":40},{"type":44,"investigatorFullName":45,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","FengYan Jin","100596416",false,"NCT07045168","Risk-adapted Therapeutic Strategy in +1q NDMM","Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study","Inclusion Criteria:\n\n* Age \\>=18, or \\>=65 and fit according to IMWG-FI.\n* Newly diagnosed NDMM by 2014 IMWG criteria.\n* Adequate organ function for systemic therapy.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Active infections requiring systemic treatment.\n* Unstable angina, NYHA class III-IV heart failure, or uncontrolled arrhythmias.\n* History of hematologic or solid tumors treated with chemo\u002Fradiotherapy within 5 years.\n* Current malignancies requiring therapy.\n* Refusal to participate.","ALL",{"count":54,"type":55},200,"ESTIMATED","OBSERVATIONAL","This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) status as the primary endpoint.",[59],"Multiple Myeloma",[59,61,62,63,64],"Risk-adapted therapeutic strategy","+1q MM","high-risk MM","minimal residual disease","NOT_YET_RECRUITING","2025-09-07",{"date":68,"type":69},"2025-09-15","ACTUAL",{"date":68,"type":55},{"date":72,"type":55},"2029-07-04",{"name":45,"class":6},1]